PBMWW

Psyence Biomedical Ltd. (NASDAQ:PBMWW) is a Canadian biotechnology company founded to develop botanical psilocybin-based psychedelic medicines for mental health treatment. Based in Toronto, the company operates as a subsidiary of Psyence Group Inc. and focuses specifically on treating anxiety and depression in patients facing terminal cancer diagnoses. The company represents part of the emerging psychedelic medicine sector, which seeks to leverage naturally occurring psychoactive compounds for therapeutic purposes under controlled medical supervision.